Literature DB >> 34217683

An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism: The Syncope, Anemia, Renal Dysfunction (PE-SARD) Bleeding Score.

Romain Chopard1, Gregory Piazza2, Nicolas Falvo3, Fiona Ecarnot4, Mathieu Besutti5, Gilles Capellier6, François Schiele4, Marc Badoz4, Nicolas Meneveau7.   

Abstract

BACKGROUND: Improved prediction of the risk of early major bleeding in pulmonary embolism (PE) is needed to optimize acute management. RESEARCH QUESTION: Does a simple scoring system predict early major bleeding in acute PE patients, identifying patients with either high or low probability of early major bleeding? STUDY DESIGN AND METHODS: From a multicenter prospective registry including 2,754 patients, we performed post hoc multivariable logistic regression analysis to build a risk score to predict early (up to hospital discharge) major bleeding events. We validated the endpoint model internally, using bootstrapping in the derivation dataset by sampling with replacement for 500 iterations. Performances of this novel score were compared with that of the VTE-BLEED (Venous Thrombo-Embolism Bleed), RIETE (Registro informatizado de la enfermedad tromboembólica en España; Computerized Registry of Patients with Venous Thromboembolism), and BACS (Bleeding, Age, Cancer, and Syncope) models.
RESULTS: Multivariable regression identified three predictors for the occurrence of 82 major bleeds (3.0%; 95% CI, 2.39%-3.72%): Syncope (+1.5); Anemia, defined as hemoglobin <12 g/dL (+2.5); and Renal Dysfunction, defined as glomerular filtration rate <60 mL/min (+1 point) (SARD). The PE-SARD bleeding score was calculated by summing all the components. Overall, 52.2% (95% CI, 50.29%-54.11%) of patients were classified as low bleeding-risk (score, 0 point), 35.2% (95% CI, 33.39%-37.04%) intermediate-risk (score, 1-2.5 points), and 12.6% (95% CI, 9.30%-16.56%) high-risk (score >2.5 points). Observed bleeding rates increased with increasing risk group, from 0.97% (95% CI, 0.53%-1.62%) in the low-risk to 8.93% (95% CI, 6.15%-12.44%) in the high-risk group. C-index was 0.74 (95% CI, 0.73-0.76) and Brier score 0.028 in the derivation cohort. Similar values were calculated from internal bootstrapping. Performance of the PE-SARD score was better than that observed with the VTE-BLEED, RIETE, and BACS scores, leading to a high proportion of bleeding-risk reclassification in patients who bled and those who did not.
INTERPRETATION: The PE-SARD bleeding risk score is an original, user-friendly score to estimate risk of early major bleeding in patients with acute PE.
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bleeding; pulmonary embolism; score

Mesh:

Year:  2021        PMID: 34217683     DOI: 10.1016/j.chest.2021.06.048

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  LMWHs dosage and outcomes in acute pulmonary embolism with renal insufficiency, an analysis from a large real-world study.

Authors:  Dingyi Wang; Guohui Fan; Jieping Lei; Yuanhua Yang; Xiaomao Xu; Yingqun Ji; Qun Yi; Hong Chen; Xiaoyun Hu; Zhihong Liu; Yimin Mao; Jie Zhang; Juhong Shi; Zhu Zhang; Sinan Wu; Xincao Tao; Wanmu Xie; Jun Wan; Yunxia Zhang; Shuai Zhang; Kaiyuan Zhen; Zhonghe Zhang; Baomin Fang; Chen Wang; Zhenguo Zhai
Journal:  Thromb J       Date:  2022-05-05

Review 2.  In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients.

Authors:  Géraldine Poénou; Emmanuel Tolédano; Hélène Helfer; Ludovic Plaisance; Florent Happe; Edouard Versini; Nevine Diab; Sadji Djennaoui; Isabelle Mahé
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

3.  Clinical Application of Echocardiography in Evaluating Left Ventricular Diastolic Function in Patients with Acute Pulmonary Embolism.

Authors:  Shiyang Qin; Rui Zhang
Journal:  Comput Math Methods Med       Date:  2022-05-11       Impact factor: 2.809

4.  Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis.

Authors:  Romain Chopard; Ida Ehlers Albertsen; Fiona Ecarnot; Sebastien Guth; Matthieu Besutti; Nicolas Falvo; Gregory Piazza; Nicolas Meneveau
Journal:  J Am Heart Assoc       Date:  2022-06-22       Impact factor: 6.106

5.  Anticoagulant for treatment and prophylaxis of venous thromboembolism patients with renal dysfunction: A systematic review and network meta-analysis.

Authors:  Guohui Fan; Dingyi Wang; Meng Zhang; Xufei Luo; Zhenguo Zhai; Sinan Wu
Journal:  Front Med (Lausanne)       Date:  2022-09-26

6.  Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.

Authors:  Paul L den Exter; Scott C Woller; Helia Robert-Ebadi; Camila Masias; Pierre-Emmanuel Morange; David Castelli; John-Bjarne Hansen; Geert-Jan Geersing; Deborah M Siegal; Kerstin de Wit; Frederikus A Klok
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.